Breast Cancer

Arimidex reduces risk of contralateral breast tumors compared with gold-standard tamoxifen

Published in Cancer Weekly, May 14th, 2002

Latest results from the ATAC (Arimidex, Tamoxifen Alone or in Combination) study in early breast cancer, presented at the 3rd European Breast Cancer Conference (EBCC), show that treatment with Arimidex more than halved the risk of postmenopausal women developing new tumors in the other previously healthy (contralateral) breast compared with tamoxifen.

Patients in the Arimidex treatment arm had a 58% lower risk of developing a contralateral breast tumor compared with those taking tamoxifen (OR=3D0.42, p=3D0.0068). Furthermore, in postmenopausal women with receptor-positive breast tumors, Arimidex was shown to lower the risk of contralateral breast cancer by 64%...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2002-05-14)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry